CD79A and toxoplasmosis: Our study has limitations, including the retrospective study design, the lack of clinical information, and the fact that serum samples were obtained in the United States, where there is a lack of systematic testing for toxoplasmosis (including T. gondii IgA antibodies), which may have resulted in ascertainment bias.